Julius Baer analysts say Democratic control of both the US House and Senate
after the midterms could ease a policy headwind for Swiss drugmakers by
increasing scrutiny of Trump-era international drug-pricing agreements, reducing
the likelihood those deals are enacted into law. They caution, however, that
Democrats’ focus on lowering prescription drug costs limits the case for broad
optimism across the sector.
